CLINICAL THYROIDOLOGY FOR THE PUBLIC
A publication of the American Thyroid Association
Welcome to another issue of Clinical Thyroidology for the Public. In this journal, we will bring to you the most up-to-date, cutting edge thyroid research. We also provide even faster updates of late-breaking thyroid news through Twitter at @thyroidfriends and on Facebook. Our goal is to provide patients with the tools to be the most informed thyroid patient in the waiting room. Also check out our friends in the Alliance for Thyroid Patient Education. The Alliance member groups consist of: the American Thyroid Association, Bite Me Cancer, the Graves’ Disease and Thyroid Foundation, the Light of Life Foundation, ThyCa: Thyroid Cancer Survivors’ Association, Thyroid Cancer Canada, Thyroid Cancer Alliance and Thyroid Federation International.
The American Thyroid Association (ATA) extends its appreciation to all of the patients and their families that are part of the ATA community — our Friends of the ATA. It is for you that the ATA is dedicated to carrying out our mission of providing reliable thyroid information and resources, clinical practice guidelines for thyroid detection and treatments, resources for connecting you with other patients affected by thyroid conditions, and cutting edge thyroid research as we search for better diagnoses and treatment outcomes for thyroid disease and thyroid cancer.
As we think of all those who make a difference in our lives this holiday season, we thank you for being part of the ATA family and for all of the Friends of the ATA who support our mission and work throughout the year to support us. We invite you to help keep the ATA mission strong by choosing to make a donation that suits you – it takes just one moment to give online at: www.thyroid.org/donate and all donations are put to good work. The ATA is a 501(c)3 nonprofit organization and your gift is tax deductible.
The editorial board of CTFP, the ATA Board of Directors, Members, and ATA Headquarters Staff, wish you the best this season and look forward to being part of your thyroid network in 2019.
In this issue, the studies ask the following questions:
- What affects quality of life in thyroid cancer patients?
- What drives patients with hypothyroidism to seek alternative therapies?
- What factors predict the outcome of RAI therapy in Graves’ disease?
- Does RAI therapy for Graves’ disease in women increase the risk of neonatal hyperthyroidism in their babies?
- Does individualized RAI therapy dosing have an effect on thyroid cancer outcomes?
- Does levothyroxine therapy normalize cholesterol levels in hypothyroid patients?
We welcome your feedback and suggestions. Let us know what you want to see in this publication. I hope you find these summaries interesting and informative.
— Alan P. Farwell, MD, FACE